Proposal to widen access to pertussis (whooping cough) vaccine

14 May 2019 - PHARMAC is seeking feedback on a proposal to widen access to funded pertussis (whooping cough) vaccine ...

Read more →

Proposal for changes to funded vaccines in the National Immunisation Schedule

9 May 2019 - PHARMAC is proposing to make changes to the funding of vaccines in the National Immunisation Schedule ...

Read more →

First FDA approved vaccine for the prevention of dengue disease in endemic regions

1 May 2019 - The U.S. FDA announced today the approval of Dengvaxia, the first vaccine approved for the prevention of ...

Read more →

Dynavax announces European Medicines Agency accepts marketing authorisation application for Heplisav-B for prevention of hepatitis B in adults

28 March 2019 - Dynavax Technologies today announced that the EMA has accepted the Company’s marketing authorisation application for review ...

Read more →

Bavarian Nordic announces FDA delay in the review of the biologics license application for MVA-BN smallpox vaccine

11 March 2019 - Bavarian Nordic today announced that it has received information from the U.S. FDA that the review ...

Read more →

Teenager's meningococcal death prompts coroner to urge free B-strain vaccine

5 March 2019 - A coroner wants the Tasmanian Government to offer free meningococcal B strain vaccines for people younger ...

Read more →

Themis Bioscience receives FDA fast track designation for Chikungunya vaccine candidate

25 February 2019 - Themis Bioscience announced today that the United States FDA has granted fast track designation to the ...

Read more →

Pfizer's best selling drug is actually a vaccine—and its price keeps increasing

5 February 2019 - Pfizer is perhaps best known as the maker of drugs such as Viagra. But the pharmaceutical ...

Read more →

Public consultation – draft cost recovery implementation statement for listing medicines on the PBS and designated vaccines on the NIP

1 February 2019 - After consultations with industry representatives during 2018, the Department of Health is releasing the draft statement ...

Read more →

Merck receives breakthrough therapy designation from FDA for V114, the company’s investigational 15-valent conjugate vaccine for the prevention of invasive pneumococcal disease, in infants, children, and adolescents

30 January 2019 - Merck today announced that V114, the company’s investigational 15-valent pneumococcal conjugate vaccine, has received Breakthrough Therapy Designation ...

Read more →

FDA approves use of 0.5 mL dose of Fluzone Quadrivalent (influenza vaccine) in children as young as 6 months of age

23 January 2019 - The 0.5 mL dose is now approved for use in children 6 months through 35 months of ...

Read more →

Sanofi UK marketing authorisation granted for Sanofi Pasteur’s trivalent influenza vaccine (split virion, inactivated) high dose (TIV high dose)

21 January 2019 - UK is the only European country where TIV high dose is approved. ...

Read more →

Approval for Seqirus flu vaccine

15 January 2019 - Seqirus has announced European approval of its new cell-based quadrivalent influenza vaccine. ...

Read more →

FDA approves expanded use of Adacel (Tdap) vaccine for repeat vaccination

14 January 2019 - First and only vaccine approved in the U.S. for repeat vaccination 8 years or more after the ...

Read more →

ImmusanT secures fast track designation for lead therapeutic vaccine candidate Nexvax2 for patients with celiac disease

2 January 2019 - Nexvax2 has been designed to potentially restore immune tolerance to gluten in patients with celiac disease. ...

Read more →